Loading ......
DM1 is a thiol-containing maytansinoid that binds tubulin with extraordinary potency and has been conjugated to a wide range of antibodies since the earliest clinical antibody-drug conjugates. Its chemistry permits several linkage strategies, from reducible disulfides to non-cleavable thioethers, and each strategy produces a conjugate with distinct circulatory behaviour. Because DM1 conjugates have accumulated across many development programmes, the analytical community has an unusual opportunity: the same payload can be compared across different antibodies, linkers and dosing schedules, revealing which aspects of conjugate behaviour are attributable to the payload and which to the carrier. Realising that opportunity requires assays that measure DM1-bearing conjugates consistently, without cross-reacting with the growing family of auristatin-based molecules that share similar conjugation chemistry.
Figure 1. DM1 ADC ELISA for Maytansinoid Conjugate Quantitation across Antibody Platforms.
The analytical challenge with maytansinoid conjugates lies in the payload's hydrophobicity and its tendency to promote aggregation. Conjugates carrying multiple DM1 units per antibody can aggregate during storage, and aggregated material behaves differently in immunoassays than the monomeric species, producing results that drift as a preparation ages. Linker choice compounds the problem: reducible linkers release payload in the presence of thiols, including those present in some sample matrices, whereas non-cleavable linkers retain the payload until the antibody is proteolytically degraded. An assay that measures intact conjugate must therefore be characterised for its behaviour with each linker type, and its calibration must reflect the payload distribution of the reference material. Laboratories that establish these characteristics before routine use find that results from different programmes can be compared meaningfully, which is precisely the value that a well-characterised DM1 assay offers to the field.
| DM1 Conjugate Species and Payload Parameters | Details |
| DM1 Maytansinoid Payload | A benzoansamacrolide that inhibits microtubule assembly at the vinca site, DM1 is too potent and too hydrophobic for systemic administration and requires antibody targeting. Its thiol group enables conjugation through disulfide or thioether chemistry, and the resulting linkage determines release kinetics. |
| Intact DM1 Conjugate | The intact species carries antibody, linker and maytansinoid in a single molecule and is the form capable of target-directed delivery. Its measurement requires reagents that recognise the conjugated antibody rather than the bare carrier, and that do not cross-react with auristatin conjugates. |
| Payload-to-Antibody Ratio | Conjugates with higher payload loads deliver more drug per binding event but clear faster and aggregate more readily. Characterising the average load of a preparation explains differences in exposure that concentration measurement alone cannot resolve. |
| Linker Stability | Reducible and non-cleavable linkers behave differently in circulation and in sample matrices. Documenting stability for each linker type ensures that an apparent exposure difference reflects biology rather than pre-analytical degradation. |
The value of a payload-class assay emerges most clearly when conjugates built on different antibodies are compared under equivalent conditions. Trastuzumab emtansine delivers DM1 to HER2-expressing cells through a non-cleavable linker, while cantuzumab mertansine targets a carbohydrate antigen through a reducible linkage, and the two molecules therefore differ in both targeting and release mechanism. Measuring each with a format suited to its linker, and interpreting the results against a common payload reference, reveals how much of the observed exposure profile derives from the antibody and how much from the chemistry. Such comparisons inform platform decisions in organisations developing multiple conjugates, and they support regulatory arguments about the generalisability of manufacturing changes. They also help explain clinical observations that appear anomalous within a single programme, since a finding that looks unusual for one conjugate may be entirely typical for its payload class once comparative data are available. Building this comparative capability requires assays that share methodology, and it requires antibodies that recognise the payload independently of the carrier.
| Products | Core Advantages | Primary Applicable Scenarios |
| DM1 ADC ELISA Kit | A payload-directed assay that detects intact DM1-bearing conjugate across antibody carriers, with reagents characterised for specificity against maytansinoid payloads and negligible cross-reactivity toward auristatins. The format supports quantitative comparison between conjugates that share payload chemistry but differ in antibody or linker. | Cross-program conjugate comparison, platform qualification, and payload-class characterisation. |
| Trastuzumab emtansine (ADC) ELISA Kit | A molecule-specific assay for the HER2-directed DM1 conjugate, using reagents that recognise the intact conjugate in human serum and plasma. The method supports the dilution ranges required in clinical pharmacokinetic sampling and delivers reproducible quantitation across lots. | Clinical exposure monitoring for HER2-directed therapy, exposure–response analysis, and biosimilar comparability studies. |
| Cantuzumab mertansine (ADC) ELISA Kit | A conjugate-specific assay for a maytansinoid conjugate built on a different antibody and linker, allowing direct comparison of exposure behaviour between conjugates that share payload but differ in delivery chemistry. The format performs reliably in serum and plasma and supports serial sampling. | Comparative linker studies, cross-conjugate exposure benchmarking, and research into carrier-dependent pharmacokinetics. |
| Rabbit Anti-DM1 Polyclonal Antibody | A polyclonal reagent recognising maytansinoid payload, suitable for detection in custom immunoassays, for immunohistochemical localisation of conjugated drug or for verifying payload presence after conjugation. Its broad epitope profile provides robust signal across linker chemistries. | Custom assay development, tissue localisation studies, and conjugation verification during manufacturing. |
Because DM1 conjugates span multiple antibodies and linkers, the portfolio is designed for comparison rather than for isolated measurement.
DM1 conjugates have been part of clinical development long enough to generate a body of comparative experience, and that experience is only useful if it can be measured consistently. A payload-class assay, together with molecule-specific methods for representative conjugates and a payload-recognising antibody for custom work, makes such consistency achievable. The DM1 ADC ELISA Kit, the Trastuzumab emtansine (ADC) ELISA Kit, the Cantuzumab mertansine (ADC) ELISA Kit and a polyclonal anti-DM1 antibody together support exposure comparison, linker assessment and assay development within a single coherent framework. For laboratories serving multiple conjugate programmes, this combination reduces duplication while improving the interpretability of results across molecules.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIABL311 | DM1 ADC ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25417 | Anti-CCL2 (Carlumab)-SMCC-DM1 (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIA-JY25418 | Anti-CCL2 (Carlumab)-SPDB-DM4 (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......